Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis.

Abstract

BACKGROUND:

Fingolimod is an effective treatment for active relapsing-remitting multiple sclerosis (MS). Discontinuation of therapy may be followed by recurrence of disease activity. Thus, female MS patients may be at risk of relapse during pregnancy after stopping fingolimod.

OBJECTIVES AND METHODS:

To report the disease course during pregnancy of five women who interrupted therapy with fingolimod for pregnancy.

RESULTS:

All patients experienced relapses during pregnancy and/or postpartum after stopping fingolimod.

CONCLUSION:

The risk of recurrence of disease activity during pregnancy after stopping fingolimod may be substantial. This should be considered and discussed with MS patients who are planning to become pregnant.

• Authors: Ingrid Meinl, Joachim Havla, Reinhard Hohlfeld, Tania Kümpfel
• Journal: Multiple sclerosis (Houndmills, Basingstoke, England) (Mult Scler) Vol. 24 Issue 7 Pg. 991-994 (06 2018) ISSN: 1477-0970 [Electronic] England
• PMID: 28920764 (Publication Type: Journal Article)

Chemical References

• Immunosuppressive Agents
• Fingolimod Hydrochloride

Topics

• Adult
• Disease Progression
• Female
• Fingolimod Hydrochloride (therapeutic use)
• Humans
• Immunosuppressive Agents (therapeutic use)
• Multiple Sclerosis, Relapsing-Remitting (drug therapy, pathology)
• Pregnancy
• Pregnancy Complications (drug therapy, pathology)
• Recurrence